Predictive Biomarker Sciences Inc. is a privately held corporation based in Mesa, Arizona, and founded in 2006 with funding from private investors, mostly based in Arizona. It is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen). Predictive Biomarker Sciences develops cancer treatment technologies for pre-clinical research to pharmaceutical clients. Its technology analyzes primary tumor cell lines' responses to investigational drugs through the use of fluorescent reporters.